




Introduction: Improved care for patients with cancer is leading to an exponential growth in 
cancer survivors that may number over 20 million by 2024. I utilized data from the HealthCare 
Cost and Utilization Project (HCUP) along with a review of the contemporary literature to 
establish an understanding of the needs of cancer survivors in the United States. 
Methods:  After performing a Medline search to identify the needs of cancer survivors and 
relevant side effects, I utilized the National (Nationwide) Inpatient Sample (NIS) and Nationwide 
Emergency Department Sample (NEDS) to identify trends for radiation cystitis, radiation bowel 
problems and fistula disease.  Descriptive statistics are presented including initial rates per 
100,000 of visits and discharges, hospital charges, costs, and ranges as well as standard 
deviation. I performed a regression analysis to assess linearity of the trends in the rates of visits 
to the emergency room (NEDS) and discharges from hospitals (NIS). I used Z statistical tests to 
assess the statistical significance of changes in interval scale data such as costs and charges 
for first year measurements compared to most recent measurements in HCUP.  All analyses 
were weighted using NIS and NEDS weights and covariance matrices. P-values were computed 
using an alpha of 0.05 and 95% confidence intervals as criteria for statistical significance.  
Results: The literature review produced 86 scientific articles for review. NED and NIS show that 
emergency room visits (P=0.0009) and discharges (P=<0.0001) for radiation cystitis (ICD-9 
595.82, irradiation cystitis) per 100,000 increased from 1997 to 2014. The relative discharge 
proportion of men vs. women changed over this time period as well with men accounting for 
66.8% of all discharges for radiation cystitis in 2006 and 81.7% of all discharges in 2015 
(P<0.0001) and their average age increased significantly from 74.6 years (standard error 0.55) 
in 1997 to 77.0 years (standard error 0.46) in 2015 (P = 0.0014). 
Conclusion: With 16.9 million people, cancer survivors currently number more than twice the 
size of New York City and the number with side effects is increasing significantly. Literature 
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review indicates that there are many opportunities to improve the care of this growing 
population. Recommendations for future research and policy development to increase 








In 2018 there were 1.74 million estimated new cancer cases in the United States (US), 
19% of which were from pelvic malignancies ("Cancer Facts and Figures," 2018). The current 
definition of a cancer survivor includes patients and their care providers from the time of 
diagnosis of cancer until death (Survivorship, 2019).  For the last century a substantial focus on 
improving cancer therapies has resulted in continuously improved survival with 16.9 million 
cancer survivors alive today in the US. This number is exponentially expanding, with a 
possibility to exceed 20 million in 2024; more than twice the current population of New York City 
(Figure 1) (Bluethmann, Mariotto, & Rowland, 2016). Furthermore, up to 40% of these survivors 
have been treated for pelvic malignancies such as prostate cancer, colorectal cancer and 
various gynecology related malignancies that may have effects on the genitourinary tract 
(DeSantis et al., 2014).  
During treatment, there has always been an appropriate focus on cancer cure however, 
after treatment many patients report difficulty with side effects that may be addressed by their 
providers. Because of this appropriate focus on survival, the follow-up care in cancer survivors 
has concentrated overwhelmingly on surveillance for recurrence while other important health 
concerns may often go ignored (Earle & Neville, 2004; Edgington & Morgan, 2011; Snyder et 
al., 2008). Because of this, over a decade ago the President’s Cancer Panel published a report 
highlighting the need for improvement in patient education and awareness as well as the 
establishment of follow-up survivorship care plans (SCP) to facilitate support for cancer 
survivors (United States. President's Cancer Panel., Reuben, & National Cancer Institute (U.S.), 
2004).   
Urinary, bowel and sexual dysfunction may result in up to 80% of patients after treatment 
for pelvic malignancies and this population represents a significant group of Americans who 
may require care after the curative treatment is finished (Madden-Fuentes et al., 2017).  
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Multimodal treatments are often chosen in these situations with radiation playing an important 
role in curative treatment as a combined or standalone therapy. However, despite the 
recognition of the increasing numbers of survivors in the US, there is a significant lack of 
longitudinal research with attention to the long term side effects from these lifesaving definitive 
therapies.  
Of the 14 million cancer survivors in the US in 2012, 2.8 million had undergone 
treatment for prostate cancer (Siegel et al., 2012).  These numbers are projected to increase in 
the next 10 years as the US population ages and as a result, long-term health issues related to 
survivorship in the prostate cancer population are emerging as an important public health 
concern.  Prostate cancer is the most prevalent cancer in men, diagnosed in more than 241,000 
people each year (DeSantis et al., 2014; Siegel et al., 2012).  More than 90% of prostate 
cancers are diagnosed in the early stage, which has a 5-year survival rate approaching 100% 
and the 10- and 15-year survival rates are 98% and 91%, respectively. In a study of 14,000 
prostate cancer patients who underwent surgery with median follow up of 7.6 years, the non-
prostate cancer mortality rate was double that of the prostate cancer-specific mortality (Guzzo et 
al., 2010).  This long survivorship trajectory of prostate cancer patients makes preventive 
medical care for their side effects of therapy of high importance as many may experience long 
term side effects of their life saving therapy (Grunfeld & Earle, 2010).  
The goal of this paper is to utilize data from the HealthCare Cost and Utilization Project 
(HCUP) including its component databases; the Nationwide Emergency Database (NED) and 
the National (Nationwide) Inpatient Sample (NIS) along with a comprehensive review of the 
contemporary literature to realize two objectives. First is to describe the trends in utilization of 
definitive radiation therapy (Brachytherapy, external beam radiation therapy) versus surgery 
over the last decade in the United States. The second is to evaluate whether radiation toxicity is 
increasing in the United States. Analysis of this secondary objective includes evaluation of three 
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major known side effects from radiation therapy; radiation cystitis, urinary fistula, and radiation 
induced gastrointestinal problems. The overall goal of this paper is to utilize the tenants of public 
health with emphasis on assessment and policy development to discuss improving the quality of 
life of this population. By establishing an understanding of the burden of disease (assessment) 
in patients who have undergone treatment with radiation we then will develop recommendations 
to provide improved resources and care to this rapidly growing population (policy). 
Methods: 
Literature review:  
I performed a systematic Medline search from its start until January 2019 to identify 
studies targeting survivorship issues for genitourinary neoplasms. With the assistance of a 
medical librarian I searched for human subject studies in English using the search terms “cancer 
survivorship” and “urogenital neoplasms” and also searched for the following terms: ‘pelvic 
radiotherapy’, ‘radiation cystitis’, ‘hemorrhagic cystitis’, ‘fistula’, ‘radiation proctitis’, and ‘side 
effects’.  I screened the relevant studies and extracted data and categorized the papers into 
non-urology related or urology related. In the urology related articles I scanned abstracts for 
relevant studies to exclude commentary papers, editorials or ones not relevant to the review. I 
also included government and non-government agency reports (grey literature) as well as 
communications focusing on survivor concerns currently available through well-established 
government entities and non-government organizations.  
Database Review: 
I reviewed well established, pre-existing available databases for their possible 
contribution to this project within the United States. I evaluated SEER, various cancer 
databases such as CAPSURE at the University of California San Francisco, the CPDR 
database (Center for Prostate Disease Research), and various facility and state databases.  I 
found that the one of the most robust freely available resources is the HealthCare Cost and 
6 
 
Utilization Project (HCUP). This is a group of databases that are from the federal government 
through the Agency for Healthcare Research and Quality (AHRQ) and consists of the National 
(Nationwide) Inpatient Sample (NIS), Nationwide Emergency Database (NEDS), Kids Inpatient 
Database (KID), and the Nationwide Readmission Database (NRD). HCUP also has state level 
data that can be used for analysis and research as well. 
I capitalized on the HCUP databases with emphasis on the National (Nationwide) 
Inpatient Sample (NIS) and the Nationwide Emergency Department Sample (NEDS). Data from 
both of these are derived from a 20% stratified sample of all hospital-based emergency 
departments and hospital admissions in the United States ("HCUP Sample Design: National 
Databases," 2018). These contain information on patient demographics including clinical 
specifics such as diagnostic codes, procedures performed on admission or in the emergency 
department, readmission rates, disposition including discharges or admission to the hospital, 
and financial data based on charges that were submitted. This secondary data is generated 
from billing events for patients admitted to hospitals. When a patient is admitted to a hospital in 
a participating state, that hospital creates a bill for the admission with diagnosis codes. That 
data is sent to the state agency tasked with maintaining these types of information. The state 
stores the data and then ships it to the federal component of HCUP. Prior to 2012, the sampling 
strategy included evaluating all of the discharges from a regional sampling of the hospitals that 
were participating in HCUP. This was changed after 2012 to include a random sampling of the 
discharges from all of the hospitals that participated in HCUP.  These discharges were weighted 
based on the census data in the region. These discharge weights are calculated for NIS data by 
stratifying the NIS hospitals on the same variables that were used for creating the sample 
including the Census division, the location (urban or rural), teaching status, bed size, and 
hospital ownership. The weight is then calculated for each stratum, by dividing the number of 
discharges in that stratum, obtained from HCUP and the AHA data, by the number of NIS 
discharges in the stratum. Weighted estimates are then calculated by applying the discharge 
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weights to the sample discharges to give an estimate of the number of discharges for the entire 
country.  After this standardization  the data is made available for review by researchers, 
policymakers and clinicians ("Producing National HCUP Estimates," 2018).  
These databases are available for purchase and are only accessible after a significant 
amount of training on patient safety, privacy, and statistical analysis which I completed 
(Appendix A). Research analysis was conducted after IRB approval at both Duke University and 
the University of North Carolina at Chapel Hill (Appendix B).  
 I identified all encounters based on diagnoses listed in the International Classification of 
Diseases, Ninth Revision (ICD-9).  For this paper I limited the analysis to ICD-9 in order to avoid 
confusion and obfuscation brought about from the change to ICD-10-CM in October of 2015. 
While there are multiple known side effects from radiation therapy, I placed emphasis on those 
side effects most likely captured by inpatient hospital based events in the HCUP NIS and NED 
database including radiation cystitis (ICD-9 595.82, irradiation cystitis), radiation proctitis (ICP-9 
569.3, hemorrhage of rectum and anus, 558.1 radiation gastroenteritis) and fistula disease 
(ICD-9 599.1, urethral fistula).  Incontinence and sexual dysfunction are well known side effects 
from surgical and radiation treatment for prostate cancer but are most often treated in the 
outpatient setting and the maturity of the HCUP datasets to evaluate outpatient treatments and 
procedures performed in Ambulatory Surgery settings are not yet robust enough to provide 
mature and complete data in order to make valid conclusions. 
Descriptive statistics are presented as provided by the initial HCUP database including 
initial rates per 100,000 of visits and discharges, hospital charges, hospital costs, and ranges as 
well as standard deviation. I performed regression analyses assessing the trends over time  in 
the rates of visits to the emergency room (NEDS) and discharges from hospitals (NIS) with 
respect to year using the standardized national estimates from the NIS and NEDS; both logistic 
regression and ordinary linear regression were used depending on the  scale of the measure 
being analyzed. The key objective of these methods was to assess the statistical significance of 
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linear trends over time, e.g., from 1997 to 2014, a technique to determine if significant changes 
occurred during that time period.   I also used statistical tests such as the Z-test as appropriate 
based on data characteristics and distribution to assess the statistical significance of changes in 
costs and charges for  first year measurements compared to most recent measurements in 
HCUP (Pagano & Gauvreau, 2000). All analyses were weighted using NIS and NEDS specific 
estimated weights and covariance matrices. An alpha of 0.05 and 95% confidence intervals 
were used as criteria for statistical significance. All analyses were performed using SAS, version 
9.4 (SAS Institute, Cary, NC). 
Results: 
Literature review: 
 The initial literature review produced 86 articles and reports. The preliminary analysis 
limited these to the English language including papers with original data, and those that met 
criteria for peer review. This produced 36 articles and seven reports that were arranged into 
general categories consisting of review articles, original research, biopsychosocial articles, 
guidelines, specialty society recommendations, white papers, and clinical models in order to 
provide care to this population. Over the last decade the use of radiation therapy has not 
increased significantly. In fact the proportion of radiation treatment modalities used for prostate 
cancer has decreased while the use of surgery has increased over the years and the use of 
brachytherapy  has gone down while the use of external beam radiation therapy has remained 
relatively stable (Figure 2) (Burt, Shrieve, & Tward, 2018; Dinan et al., 2012).  Similar results 
have also been reported by other authors as well with Martin et al in 2014 showing that 
brachytherapy use was decreasing while the use of surgery was going up (Figure 3) (Martin et 
al., 2014).  
Data Analysis of HCUP: 
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The HCUP NEDS included complete data from 2006 to 2014 and partial data for 2015 
because of the change to ICD-10-CM in October of 2015.  I evaluated for trends in the 
presentation to the emergency room and admission to the hospital for these side effects of 
radiation therapy over time to establish the burden of disease for this patient population. 
Analyses of all patients presenting to the nation’s emergency departments for radiation induced 
bowel injury showed a decrease over time for the population as a whole (males and females 
combined). Specifically radiation gastroenteritis (ICD-9 558.1) went from 0.86 per 100,000 in 
2006 to 0.66 per 100,000 in 2014 (R2: 0.79, P=0.001) (Graph 1). The average length of hospital 
stay remained stable with an average of 3.5 days (median: 3, standard error: 0.16) for radiation 
gastroenteritis. Subgroup analysis mirrored these findings with a decrease in emergency room 
presentations for both men and women in this group during this time period. However, NIS data 
showed the discharges for rectal and anal hemorrhage (ICD-9 596.3) increased significantly 
over this same time period (and a subgroup analysis based on sex mirrored this trend) (Graph 
2). To make sense of this finding I performed key personnel interviews with colorectal surgeons 
and radiation oncologists at Duke University (personal communication, Christopher Mantyh, 
MD, John Migaly, MD, Bridget Koontz, MD, 2019). These interviews revealed that the most 
commonly used ICD-9 diagnostic code for radiation induced proctitis in this group is ICD-9 code 
558.1 (radiation gastroenteritis). Therefore, the rise in rectal and anal hemorrhage (ICD-9 code 
596.3) may be from multiple other factors therefore confounding this analysis. The rates for 
emergency room visits and inpatient discharges for rectourethral fistula (ICD-9 599.1) remained 
stable from 1996 to 2015 (Graph 3).   
Because of limitations and complexity of analyzing radiation injury to the rectum I 
concentrated on radiation cystitis as a representation for side effects of radiation therapy in the 
treatment of pelvic malignancies. Limitations of HCUP did not allow following patients over time 
nor cross-referencing previous diagnoses with an index diagnosis (for instance, limiting an 
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analysis to only those with a prior diagnosis of prostate cancer). Therefore, an in-depth 
subgroup analysis on males in this group gave a representation of those who may have 
undergone prior treatment for prostate cancer. Logistic regression analysis of the  HCUP NED 
database showed that emergency room visits for men with radiation cystitis (ICD-9 595.82, 
irradiation cystitis) increased over this time period from 1.46 per 100,000 to 1.73 per 100,000 ( 
R2:0.8152, P = 0.0009) (Graph 4).  An average of 90.4% of visits were admitted to the same 
hospital (range 87.7% to 94.2%) and this admission rate did not change over time.  Men 
admitted to the hospital for radiation cystitis were significantly older (median: 77 years) than 
those released from the emergency department (median: 73.6 years) (Z: 7.96, P< 0.0001).  
Logistic regression analysis showed the rates of discharges (NIS) for both sexes per 
100,000 for radiation cystitis increased significantly from 1997 to 2014 with 3695 discharges in 
2014 alone. Subgroup logistic regression analysis for men only showed the rates of discharges 
increased significantly from 1.25 per 100,000 in 1997 to 2.00 per 100,000 in 2015 (R2: 0.8338, P 
< 0.0001) (Graph 5).  The relative discharge proportion of men vs. women changed over this 
time as well. In 2006, men accounted for 66.8% of all discharges for radiation cystitis and this 
rose significantly to 81.7% of all discharges in 2015. The median age for men discharged for 
radiation cystitis increased from 74.6 years in 1997 to 77.0 years  in 2015 (R2: 0.4575, P = 
0.0014) (Graph 6). Due to the transition from ICD-9-CM to ICD-10-CM in October 2015, the 
2015 statistics were calculated using only quarter 1-3 data and so we could not calculate an 
actual number of discharged for 2015. It was not possible to determine if patients presenting 
with radiation cystitis in this cohort had undergone primary therapy with radiation or adjuvant 
therapy because of limitations in the HCUP data set (see limitations later). 
We evaluated the data in HCUP NIS for costs and charges. The average hospital charge 
per admission for both sexes (men and women) admitted for radiation cystitis in 2015 was 
$50,249 (median: $33,328).  Actual costs were much less than charges with an overall average 
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cost for men and women of $12,789 (median: $8643). Again, the costs for men were less than 
women. Among men the average cost was $12,154 (median: $8191, standard error: $615) 
compared to $15,603 for women (median: $9639, standard error: $1589) (Z: 2.024, P = 0.04). 
Due to the transition from ICD-9-CM to ICD-10-CM in October 2015, the 2015 statistics were 
calculated using only quarter 1-3 data and so I could not calculate an aggregate cost for the 
entire year of 2015. Because of this, in order to gain an estimate of the total costs and financial 
burden of this disease process the 2014 data was used.  In 2014 there were 3695 discharges 
from the hospitals involved in HCUP for radiation cystitis. The median charge for each 
admission/discharge was $31,935 and the cost was $8,530. Multiplying these by the number of 
discharges results in an aggregate charge for 2014 of $117, 999,825 and an aggregate cost of 
$31,518,350. 
Beginning with the 2012 data, the National Inpatient Sample (NIS) was redesigned to 
optimize national estimates. The nationwide statistics for years prior to 2012 were regenerated 
using new trend weights in order to permit longitudinal analysis. Due to the transition from ICD-
9-CM to ICD-10-CM in October 2015, the 2015 statistics were calculated using only quarter 1-3 
data, and the statistics available were limited. All of the data consisted of weighted national 
estimates from HCUP National (Nationwide) Inpatient Sample (NIS), Agency for Healthcare 
Research and Quality (AHRQ) based on data collected by individual States and provided to 
AHRQ by the States.  
Discussion: 
 The overall analysis of the literature review and primary “big data” analysis from HCUP 
showed that cancer survivors are significantly increasing in numbers in the United States. 
Additionally, with the increased survival and age of this population we are likely to see 
drastically climbing requirements for resources to care for this population. There are several 
identified areas of need that came about from the literature review and the data on the 
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prevalence and increasing costs of caring for this population from the HCUP; understanding 
these will aid the public health professional in advocating for resource allocation and policy 
changes to help improve the quality of life of this population. 
Review of the literature for the current status and needs of cancer survivors in the United 
States: 
In the past, cancer survivors and their cancer specialists were appropriately focused on 
the cancer treatment and risk of recurrence which may have resulted in neglecting other 
aspects of health including side effects and the need for follow-up with their primary care 
providers for routine health maintenance (Ganz, 2009; M. E. Hewitt, Greenfield, Stovall, & 
National Cancer Policy Board (U.S.). Committee on Cancer Survivorship: Improving Care and 
Quality of Life., 2006).  The literature has not addressed this issue fully, making survivorship 
care an area where relatively little prospective research has been performed and therefore few 
evidence-based practice guidelines or navigation services exist. The 2005 Institute of Medicine 
(IOM) report, “Cancer Patient to Cancer Survivor: Lost in Transition,” highlighted this issue and 
called for research on survivorship care and development of evidence-based clinical practice 
guidelines to improve the health of long-term survivors (M. E. Hewitt et al., 2006).  
Definition of Cancer Survivorship: Who is a cancer survivor and what are their needs? 
Discussions about cancer survivorship started over three decades ago with the founding 
of the National Coalition for Cancer Survivorship (NCCS) in 1986. The goal of this organization 
was to promote the improvement of care for cancer survivors. This is when the term “survivor” 
replaced the original description of “cancer victim”. The idea at the time was (and still is today) 
that these patient had gone through a life changing event with successful therapy to cure cancer 
and now were living with the sequelae of those treatments (Survivorship, 2019).  While the 
original definition included only those patients who had completed therapy and were free of 
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cancer, this has been significantly expanded and currently includes all patients and their families 
and caregivers from the time of diagnosis of cancer to the time of death. 
Work has been done in this field for a long time prior to the creation of the NCCS.  The 
National Cancer Act originally declared the “war on cancer” in 1971 with the establishment of 
the President’s Cancer Panel. Decades later this panel published some of the first guidelines 
and opinions for the care of the cancer survivor with a publication titled “Living Beyond Cancer: 
Finding a New Balance”.  In 2005, the IOM released their groundbreaking report “From Cancer 
Patient to Cancer Survivor: Lost in in Transition”. Both of these reports highlighted the United 
States medical system’s deficits in the care of patients who had undergone treatment for various 
cancers and made significant recommendations for patient education, research, and improved 
clinical practice for this growing population 
While these started to push some policies to address shortcomings in the healthcare 
system, the needs of these survivors were still mostly unmet. In 2010, the LiveStrong foundation 
conducted a survey of 2307 cancer survivors (LiveStrong, 2010).  This exposed some very 
significant needs that continued to persist despite many of the reports that had been released 
almost a half of a decade earlier. In these surveys, cancer survivors often stated that they had 
“learned to live with their concerns” with the most common reasons cited for not obtaining care 
being “I have learned to live with this concern” (55%) and “I was told it was a side effect that 
would go away with time” (37%). Most concerning were comments indicating that many 
physicians were not trained in providing all-encompassing care for many late term side effects 
of cancer therapies: “Addressing difficulties following treatment is something none of us 
anticipated, each physician I met was wonderful but they addressed only the problem in their 
field” and “Many of the symptoms I experienced were not addressed because no one told me 
they were side effects of treatment.” Furthermore, less than half of the survey respondents 
received care for four of their most prevalent complaints (lack of energy, lack of concentration, 
sexual functioning, and neuropathy). These surveys also highlighted the significant morbidity to 
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the psychological well-being of these patients with many identifying worrisome concerns for their 
personal appearance, financial status, ability to reintegrate with the community and return to 
work, and of course recurrence of their cancer. All of which may lead to significant emotional 
morbidity including fear, grief, depression and anxiety (LiveStrong, 2010).  Overall, this data 
clearly indicated that primary care providers, cancer experts, social workers and mental health 
experts may benefit from significant opportunities at training and education in the care of this 
large population. 
An interesting field new area for prostate cancer survivors involves effects on the sexual 
and gender minority patients with prostate cancer. The National Cancer Institute (NCI) recently 
funded a survey study on gay, bisexual and men who have sex with other men prostate cancer 
survivors to establish their needs and perceptions of their status after surviving this malignancy. 
The study consisted of primary data analysis from in-depth interviews as well as Internet based 
surveys. The results indicated that these patients have specific needs and concerns about their 
life after treatment for prostate cancer many of which are related to sexual activity specific to the 
gay male population. This group (gay, bisexual and men who have sex with men (GBM)) had 
very specific concerns about their survivorship status centering on receptive versus insertive 
anal intercourse and when it was safe to resume normal activity. Interestingly, this population 
also tended to be more likely to be single and going through treatment without significant social 
support therefore presenting many more challenges to their long-term care. Another finding from 
this series of studies indicated that these patients were uncomfortable opening up to their 
providers about their sexual orientation. This can lead to barriers in recovery often including 
sensitive subjects such as incontinence and sexual function. These survey studies indicated 
that sexual activity was at the forefront of their concerns with only 12% reporting excellent to 
good function of sexual recovery after surgery, and 85% describing trouble with erections that 
were insufficient for insertive anal sex. This was the first study to address concerns and issues 
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with this very sensitive issue and indicated that one third of men after treatment for prostate 
cancer considered this form of intercourse as poor compared to prior to treatment.  
Currently, the NCI is funding an R01 level trial to evaluate whether or not sexual 
recovery programs that were designed for heterosexual men may work appropriately for the 
gay, bisexual and men who have sex with other men prostate cancer survivors population 
(Capistrant et al., 2018; Rosser et al., 2016; Ussher, Perz, Rose, Kellett, & Dowsett, 2018).  
Epidemiology of Survivorship in the US: 
Improved treatment for cancer as a result of the “war on cancer” started in the 1970s, 
this along with the advancing age of our population has resulted in exponential increases in the 
number of cancer survivors alive in the United States. In fact, the number has increased 
dramatically from an estimated 3 million people, or 1.5% of the population in 1971 to 9.8 million 
people, 3.5% of the population in 2001(Centers for Disease & Prevention, 2004) and even today 
makes up 16.9 million people, 5% of the population of the United States and will continually 
increase by 29.1% to 21.7 million by 2029 ("Office of Cancer Survivorship Statistics," 2019).  
The type of cancers that these people are surviving tend to have a significant effects on 
the organs around them. Primary malignancies that originate in the lower pelvis may require 
treatment with surgery, chemotherapy and radiation or a combination of these modalities, all of 
which may all have effects on neighboring organ systems not involved in the primary disease 
process. In women, pelvic malignancies tend to make up a significant amount of cancers with 
cancers of the uterus, ovaries, colon and rectum making up 24% of these type of malignancies. 
In men, prostate, testicle, bladder and kidney cancer account for 57% of the primary 
malignancies that this group experiences with prostate cancer being the most common 
(DeSantis et al., 2014).  In children, up to 80% of all patients diagnosed with a childhood 
malignancy will be alive after 5 years (M. Hewitt, Rowland, & Yancik, 2003). Therefore, one can 
see that over 50% of all cancer survivors may experience a malignancy with possible future 
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effects on the genitourinary system including the bladder, urethra, kidneys, ureters, and sexual 
organs. These may all result in urination, voiding, bowel and sexual symptoms as well as 
infertility and pain in the future.  
These concerns were borne out in the LiveStrong Foundation survey in 2010. It 
highlighted how common side effects which involve the genitourinary tract and urologic system 
were encountered by these patients but infrequently addressed by their care providers. 
Additionally, survivors of other malignancies such as breast cancer, rectal cancer and some skin 
related malignancies which are not genitourinary in nature did express that they often desired to 
discuss sexual function and intimacy issues but were reluctant to bring these up (Marwick, 
1999).   Specific to the genitourinary organs, many reports indicated that these patients had 
debilitating sexual side effects that they wished had been discussed prior to choosing treatment 
(Apolo et al., 2014).   In children, fertility was often a significant issue because many 
malignancies in this age group responded to systemic chemotherapy and radiation therapy with 
potential effects on fertility. Again, knowledge deficits in care providers were evident with one 
report indicating that while 86% of pediatric oncology specialists believed referral of these 
patients prior treatment for evaluation of future fertility issues was required, a mere 46% actually 
provided this service for more than half of the time (Kohler et al., 2011).   
Side effects experienced in this population: 
While radiation therapy holds tremendous value in the curative and palliative treatment 
for various forms of cancer, many of these patients may be saddled with often severe and 
debilitating problems down the road. While the current literature focused on the acute side 
effects of radiation therapy, many urinary and sexual side effects may result in up to 80% of 
patients more than two years after their lifesaving treatment. This represents a significant 
population at risk for inadequate specialty care in our health system (Madden-Fuentes et al., 
2017).  Many of these side effects also had a median time to presentation of 4 or more years 
(Ma, Hennessey, Newell, Bolton, & Lawrentschuk, 2018).  This mirrored other reports where 
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survivors presented with prostatic pubic symphysis fistula and resultant pubic bone 
osteomyelitis a median of 7 years after primary radiation therapy for prostate cancer (Gupta, 
Zura, Hendershot, & Peterson, 2015).  
These findings reflect the fact that multidisciplinary and multimodal treatment for 
malignancies have become so successful that patients are living longer. Some of these people 
now have entered their eighth, ninth and even tenth decade of life resulting in an older 
population presenting with side effects from therapy in which over two out of three may require 
treatment. Recognition and understanding of this should lead our community to continued 
investigation in the prevention, recognition and treatment of these long-term sequelae of these 
effective cancer therapies. In the urology world these involve bladder bleeding, incontinence, 
voiding dysfunction, sexual dysfunction, fecal dysfunction and scar formation often leading to 
the need for invasive and extensive medical, surgical and psychological interventions. 
Continued recognition of this and education of not only specialists but also primary care 
providers will help to improve the care of this rapidly growing population. For this paper I chose 
to focus on the side effects of radiation therapy for pelvic malignancies in cancer survivors in the 
United States. While these may include a wide range of issues such as fistula disease, scar 
tissue formation and stricture of ureters and urethra, pelvic bone osteomyelitis, radiation cystitis, 
incontinence, and sexual dysfunction and pain I focused on radiation cystitis, radiation proctitis 
and fistula disease as they were thought to be the most common side effects experienced in 
cancer survivors after definitive radiation therapy. 
Primary data analysis, Results from the Healthcare Cost and Utilization Project (HCUP) 
datasets: 
Emergency room presentations for radiation gastroenteritis decreased significantly from 
2006 to 2015 while visits for rectal and anal hemorrhage increased.  For those patients admitted 
to the hospital, the average length of stay remained stable at three days. This initial analysis 
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was very surprising as I would assume that as radiation damage decreased so would bleeding 
presentations. However, after conducting key personnel interviews with colorectal surgeons and 
radiation oncologists (Personal communication, 2019) I found that these two ICD-9 codes (ICD-
9 596.3, ‘rectal and anal hemorrhage’ and 558.1 ‘radiation gastroenteritis’) were used for very 
different clinical situations. The code for ‘rectal or anal hemorrhage’ was often used for 
situations not involving a prior history for radiation such as bleeding polyps, hemorrhoids or 
initial presentation for malignancy. These interviews also indicated that the majority of bleeding 
episodes or problems related to radiation (ICD-9 558.1, ‘radiation gastroenteritis’) were now 
successfully treated in the outpatient clinic or the ambulatory surgery setting. However, the 
HCUP ambulatory surgery database was currently not mature or robust enough in order to 
make definitive conclusions about these presentations. 
I chose to concentrate on radiation cystitis as a proxy for side effects obtained after 
radiation therapy to the pelvic organs. The limitations brought on by analyzing radiation 
gastroenteritis such as the change in site of service from inpatient to outpatient settings and 
confounding factors related to the use of this specific ICD-9 code made it difficult to obtain any 
significant conclusions from the analysis of this group. While the decreasing visits to the 
emergency room (NEDS) and rate of discharges (NIS) may be explained by a significant 
change in site of service from the inpatient to outpatient setting in this patient population other 
explanations may have involved the reduction of side effects brought on by the use of  more 
targeted radiation therapy techniques such as Intensity Modulated Radiation Therapy (3D-CRT, 
IMRT) for pelvic malignancies (Do, Nagle, & Poylin, 2011). Analysis of Medicare data indicated 
that IMRT has almost completely replaced the use of other forms of external beam radiation 
therapy such as 3D-CRT over the last decade. The perceived advantage of utilizing this form of 
delivery included lower toxicity and side effects because of its more accurate targeting and 
better ability to avoid other organs at risk such as the bladder and rectum (Dinan et al., 2012). 
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Both emergency room visits and discharges from the hospital for radiation cystitis (ICD-9 
595.82, irradiation cystitis) increased significantly over the period reviewed. Interestingly, 90.4% 
of all visits to the emergency room required an admission to the hospital. Subgroup analysis 
showed that men admitted to the hospital were significantly older than those released from the 
emergency room.  The proportion of men and women who presented to the emergency room as 
well as those discharged from the hospital changed significantly over time with the proportion of 
men rising from 66.8% of discharges in 2006 to 81.7% in 2015. Not only did the overall rate of 
discharges increase significantly, but the proportion of men admitted and discharged from the 
hospital for radiation cystitis also increasing significantly. This finding was difficult to explain 
because the use of radiation therapy for prostate cancer had been declining (Martin et al., 
2014). However, the increase in the age of men admitted to the hospital may have indicated the 
presence of survivor and length time bias to this finding; patients treated for prostate cancer live 
much longer and therefore present at a later time after more ample follow-up. While there were 
small differences in the rates of emergency room visits with subsequent admission to the 
hospital (NEDS) and discharges (NIS) for this diagnosis, these can be explained by confounding 
factors such as patients admitted to the hospital directly from outpatient clinics or other sources. 
The HCUP database captured visit events and discharges and I could not follow individual 
patients prospectively over time in order to establish the time from radiation therapy to 
presentation of side effects. 
The cost and charges analysis was one of the most striking findings with respect to 
utilizing this data to help influence policy. Charges are dollar amounts that were billed to the 
payer for various diagnoses and treatments. The costs resulted from the actual payment made. 
Therefore sometimes the analysis of charges was deceivingly high (Arora, Moriates, & Shah, 
2015).  In 2015, the average hospital charge for patients discharged from the hospital 
throughout the United States was $50,249 for radiation cystitis. While the costs in this analysis 
were much less than the charges ($12,789 per discharge versus $50,249), this disease process 
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still resulted in a staggering aggregate cost of greater than $30 million for that year alone. To 
put this in perspective, the Durham County public health overall budget for fiscal year 2018 to 
2019 was just above $26 million per year ("Durham County FY 2018-2019 Fiscal Year Budget," 
2019).  Therefore, there may be significant opportunity to dedicate resources geared towards 
prevention, education and treatment of this expensive side effects in order to save significant 
taxpayer dollars while improving the quality of life of these cancer survivors as discussed below 
in the recommendations section. 
Weaknesses and Limitations of the analysis presented here: 
 Literature review: The goal of the literature review portion of this project was to 
summarize the current published literature on genitourinary cancer survivorship with emphasis 
on providing clinicians and researchers an overview of the current status of the subject. 
However, the type of scoping project performed in this review was only able to offer a qualitative 
assessment with significant limitations on primary data analysis. This was because the field of 
cancer survivorship lacked high quality primary research including peer-reviewed articles with 
primary data, meta-analysis, and expert created guidelines (Jacobs, Jones, Gabella, Spring, & 
Brownson, 2012). Missing from the prior literature reviews was an analysis of the burdens of 
charges and costs that this patient population presented to our healthcare system throughout 
the remainder of their life. Obviously, better studies looking at overall epidemiology, distribution 
of side effects, long-term needs, treatments and the cost of these treatments are needed in this 
field. Hence, the goal of utilizing secondary data such as found in HCUP to add to this body of 
literature. 
Primary Data Analysis: Utilization of the HCUP databases including the NIS, NED and 
NRD relied heavily on the concept of secondary data analysis. The advantages of using 
secondary data in this project included the fact that it was pre-existing with very large numbers 
covering a broad cross-section of United States. It also had financial data in addition to the 
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utilization and expenditures. Since it was already funded, gaining access to this data set was 
also less expensive than conducting my own primary data gathering and recording. 
Disadvantages included being limited to the data already included within the dataset without the 
ability to influence how the data was collected. And, since data was collected elsewhere, the 
quality and completeness of the data needed to be evaluated. Despite these limitations, this 
secondary data was very valuable in the design stage serving as a starting place to form a good 
hypothesis and develop specific questions to gather quality primary data.  
There were several specific limitations to data within the Healthcare Cost and Utilization 
Project (HCUP). The NEDS and NIS represented a 20% stratified sample of all encounters in 
emergency departments and hospitals in United States and therefore may result in conclusions 
that are not generalizable to the entire nation. These databases also consisted of very large 
amounts of retrospective administrative/billing data at significant risk of errors in coding during 
the encounter or discharge of the patient thus resulting in coding bias. While all of the 
databases within HCUP were subjected to stringent quality control, it was still possible that 
coding errors may introduce spurious findings. It was also not possible to track individual 
patients across time because the data was generated based on encounters, not on individual 
patients. Therefore, a single patient may be entered into the database multiple times for multiple 
visits for the same diagnosis thus introducing bias.  
While I focused on radiation cystitis as a marker for radiation induced toxicity, 
extrapolation to other malignancies and side effects may not be direct, but it can be assumed 
that there was some degree of overlap in public health and medical care implications and 
recommendations. 
Leadership Lessons Learned: 
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Throughout this process it became evident that this review of the literature and analysis 
of the HCUP dataset was incredibly complex. HCUP has millions of data points and takes years 
of training to become an analysis expert. While I thought I would be able to do that during the 
practicum and writing of this paper, I quickly realized that I needed expert help in order to do 
more in depth and granular analysis. Therefore I established a relationship with the biostatistics 
department at Duke University; improving my team leadership skills – an important competency 
of the Leadership MPH program.  While all of the analysis in this paper was completed by me, I 
was able to obtain some funding using this exploratory initial data in order to support creating a 
relationship with them in order to perform a much more in-depth and expert future analysis of 
this very complex and large publicly available data sets and tools. The experience and lessons 
learned here will allow me to lead others in the future as it was clear that this data can be an 
invaluable resource to answer important questions in public health and medical care. 
The practical component of this project focused on learning how to take scientific 
complex data and communicate this to policymakers and stakeholders. My entire professional 
career had been spent presenting scientific data to other scientists. Policymakers are very 
different; they are motivated, smart, ambitious and savvy. They want certainty from experts 
almost in the terms of black and white recommendations and they are incredibly sensitive to the 
financial implications of decision-making. Therefore, we need to know this about our audience, 
modify our presentations and data for those concerns, and help them navigate their choices 
logically and honestly. 
Recommendations: 
The cancer survivor population is very large, currently at 16.9 million people it makes up 
more than two times the population of New York City.  While this population grows, their needs 
will increase exponentially presenting a large public health issue with the need to care for these 
people.  There are many opportunities to help with care for this population including education 
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of providers and patients, research into new therapies and prevention strategies and dedication 
of resources to better the lives of cancer survivors and their families.  
The public health approach includes the core functions of assessment, policy 
development, and assurance which are all particularly valuable within cancer survivorship. With 
assessment we have evaluated the current published literature as well as secondary data to 
establish trends in the presentation of side effects as well as cost to the American medical 
system. Through this process we will better be able to educate lawmakers and promote policy to 
provide resources and attention for this often neglected population. And, by completing 
assurance guarantee that these policy changes lead to improvement in the quality of life, 
decreased cost to the system in order to improve the overall health of people within this 
community. This public health approach must focus on a broad spectrum of people with 
emphasis on prevention, education, health promotion and multidisciplinary involvement with 
government and policymakers, patients, physicians and other community stakeholders.  
Analysis and utilization of data presented in an understandable way to influence policymakers 
and elected officials will help mobilize resources to improve the quality of life among cancer 
survivors. This will involve a collaborative, interdisciplinary effort in order to fulfill these goals 
with input from scientists, healthcare providers, policymakers, government officials, and the 
community achieved through the use of Evidence Based Public Health (EBPH) (Jacobs et al., 
2012). With the ability to analyze and define the magnitude of this problem (80% of people 
treated for pelvic malignancy have side effects), its effects on quality of life (these survivors may 
have significant loss in QOL) and the detrimental effect on the health of this population (Gupta & 
Peterson, 2014) we can educated policy makers about the need to dedicate resources such as 
funding for research, education and medical care and treatment of this large segment of the 
population in order to improve the quality of life.  
24 
 
While classically taught to physicians, evidence-based medicine (EBM) has provided a 
useful framework for the care and treatment of individual patients. This thought process, 
popularized in the 1990s, emphasizes the importance of three inputs into clinical decision-
making; the clinical state and circumstances, research evidence, and patient preferences. In 
using this, the clinician is required to weigh objective evidence (research evidence) along with 
the wishes of the patient and the specific clinical situation using clinical judgment and expertise 
to help mitigate conflicts between these three in order to arrive at the most logical and best 
supported plan for that individual patient. Evidence based public health (EBPH) is very similar 
but focuses on the population as a whole and making decisions and policy recommendations in 
order to improve the health of a population. While there are some similarities to EBM such as 
the reliance on the best available data and clinical expertise EBPH differs significantly in that 
these concepts need to involve many more skills such as program planning, community 
engagement, dissemination and of course assessment and assurance. Another significant 
difference is that the quality of evidence in EBPH may not be considered to be as high as in 
EBM. There are much fewer randomized controlled trials and EBPH relies more heavily on 
observational studies, surveillance, and quasi-experimental designs. Involvement of a much 
wider multidisciplinary input is also required for the public health component in evidence-based 
practice. The newest concept of evidence-based practice (EBP) helps to bridge the gap and 
involves a multi-disciplinary perspective in order to combine five components designed to 
improve the health of the population; the best available research evidence, the client or 
populations characteristics and states along with their needs, the resources available, individual 
decision-making, and the environment and organizational context (Satterfield et al., 2009). With 
this analysis I have concentrated on introducing some of the most contemporary and best 
evidence from HCUP and combined that with a review of the contemporary literature to 
establish the population’s characteristics and needs as well as to define some of the resources 
available in our current environment to help make policy recommendations. The use of big data 
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without the benefit of randomized comparison groups is consistent with EBP and with careful 
assessment of threats to validity such as sources of bias and other confounders can contribute 
to policy recommendations as are proposed here.   
Development of the following recommendations are based on public health’s working 
knowledge of the socio-ecological model of health behavior which emphasizes interventions at 
the individual, interpersonal, community, and policy level in order to maximize potential 
outcomes knowing that interventions are more effective when they incorporate actions at 
multiple levels (Karen Glanz & National Cancer Institute (U.S.), 2005).  Many authors have 
clearly shown that in order to influence policy the combination of quantitative data with 
qualitative data in a well-thought-out presentation to policymakers is most effective (Allen & 
Preiss, 1998).One must understand that in order to make policy recommendations that policy 
makers value many other inputs into their decision process other than just pure data. These 
may include their own values, competing sources of information, other policy issues that are on 
the table at the same time and their own personal experience (Lomas, 2005; Lomas & Brown, 
2009; Schilling, Giles-Corti, & Sallis, 2009). Public health experts need to understand that these 
policymakers utilize this information differently than we as physicians and scientists and should 
capitalize upon this (Choi et al., 2005). 
Finally, implementation of programs with these thoughts in mind must also be 
progressive. They should start with small changes leading to improve resources and knowledge 
for cancer survivors but through continuous and dedicated commitment to the process should 
over time promote change in the healthcare for these patients. This "incremental approach" has 
been shown much more effective and leads to better sustainability than programs that focus on 
“getting everything at once” (Johnson & Broder, 1996). As scientists, we must promote a 
commitment for advocacy for this population of cancer survivors and continuously develop and 
cultivate strong partnerships among researchers, patients and their advocates, policy makers 
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and specialty societies in order to ensure that recommendations are founded in scientific data 
all the while tailored so the message is short, concise and easy to understand (Brownson, 
Chriqui, & Stamatakis, 2009; Jacobs et al., 2012). 
Individual level recommendations: 
At the individual level, programs must be developed to engage healthcare providers and 
to provide information to survivors and their families.  
1. Primary care providers, cancer experts, social workers and mental health experts 
may benefit from significant opportunities at training and education in the care of 
this large population: 
Consideration should be given from licensing boards to promote requirements for 
continuing medical education in these subjects. Much in the same way that CME is now 
required for opioid subscriptions in light of the devastating opioid epidemic, requirements should 
be made for minimal education program that are already in place for maintenance of certification 
and licenses ("Conrtrolled Substances CME Requirements," 2019). 
2. Implementation of a widely available interactive survivorship care plan and 
navigation tool: 
The Institute of Medicine (IOM) and the American Society of Clinical Oncology (ASCO) 
have both called for the development and use of survivorship care plans (SCP) to give patients 
“a personalized treatment summary, information on possible late and long-term effects, 
information on signs of recurrence, and guidelines for follow-up care” (M. E. Hewitt et al., 2006).  
While the original intention was to provide a document to summarize the diagnosis and 
treatment of cancer, the Movember foundation is now investigating a combination of 
survivorship care plans along with a navigation tool to provide information to patients as they 
journey through survivorship after the completion of the primary therapy. Widely available 
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Internet-based tools and applications can be easily accessed by the majority of Americans and 
this form of communication may significantly increase understanding of patient’s needs, 
knowledge about possible side effects and available treatments along with access to care 
(Perrin & Duggan, 2015). 
Interpersonal and community level recommendations: 
At the interpersonal and community level, support networks must be developed in order 
to ensure sustainability along with changes at the community level to increase access to care 
for survivors living in the United States (K. Glanz & Bishop, 2010).  
 
3. Automated patient navigation is a promising tool to improve the care of cancer 
survivors at the interpersonal and community level as well:  
 Patient navigators, sometimes called health coordinators or community health workers, 
are individuals who are trained to assist patients with navigating the health care system and 
ensure the removal of barriers encountered by patients while seeking screening, diagnosis or 
treatment (Freeman, 2006). While effective, this service may be prohibitively expensive but may 
be able to be automated with today’s technology. Investing resources and money into 
development of a widely available application may pay off significant dividends in the end. 
4. Survivorship care planning can be used to improve care:  
An improvement in communication between the cancer specialist and primary care 
provider regarding potential consequences of lifesaving cancer therapy and issues related to 
survivorship care, may help improve the care of prostate cancer survivors.  The IOM and ASCO 
have both called for the development and use of Survivorship Care Plans (SCP) which detail the 
patient’s treatment history and explicitly lay out guidance for survivorship care (M. E. Hewitt et 
al., 2006). The IOM report specifically recommends that patients receive “a personalized 
treatment summary, information on possible late and long-term effects, information on signs of 
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recurrence, guidelines for follow-up care.” Improved coordination and communication between 
cancer specialists and primary care physicians regarding long-term sequelae of cancer 
survivors has been referred to in the past as the “shared care model”. 
5. Development of “shared care models” for cancer survivorship care in health 
systems:  
Given the complexity of the health care needs for cancer survivors, a “shared care” 
model has been proposed where the cancer specialist and primary care provider (PCP) both 
take responsibility in caring for different aspects of the survivor’s needs in a coordinated and 
collaborative fashion (Owusu & Studenski, 2009).  A shared care model is ideal because 
specialists who treat cancer (radiation oncologists, medical oncologists and urologists, who are 
not trained in primary care) may be uncomfortable managing many long-term health 
recommendations. Conversely, primary care providers are very seldom trained with in-depth 
knowledge of many of the common side effects discussed in this paper such as radiation 
cystitis, radiation proctitis and fistula disease. The cornerstone of shared care is communication 
and coordination among providers – which is currently suboptimal in the care of cancer 
survivors and must be improved (M. E. Hewitt et al., 2006).   However, the utility of a shared 
care model will be limited if patients have difficulty accessing care thus requiring policy level 
interventions as well. 
Policy level recommendations: 
 The components to attack at the policy level should include changes to health care 
systems, social services, and advocacy (Grunfeld, Earle, & Stovall, 2011). 
6. Congress and the NIH must increase funding for research related to cancer 
survivorship with emphasis on side effect prevention and management: 
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 Despite the large number of prostate cancer survivors and well-documented need to 
improve their care there is still no published research using SCPs in prostate cancer survivors. 
Further, few studies (in any cancer) have evaluated the effect of SCPs on clinical care of 
survivors (Salz et al., 2014; Salz, Oeffinger, McCabe, Layne, & Bach, 2012). 
7. Added requirements for healthcare facilities and healthcare systems to provide 
coordinated specialty care for this population:  
This is already being done in many other countries such as in Canada where Cancer 
Care Ontario is responsible for all cancer related services in the province of Ontario. They have 
undergone a major alignment in their policies that change the reimbursement and resources 
allocation for those providing cancer care to include evidence-based guidelines and 





Figure 1: Currently there are more than 15 million cancer survivors living within the United States 
alone. This chart clearly shows that the growth is increasing logarithmically and by the year 2040 
there may be over 20 million cancer survivors within United States, this is a population well over 
twice the size of New York City. (Bluethmann, S. M., Mariotto, A. B., & Rowland, J. H. (2016). 
Anticipating the "Silver Tsunami": Prevalence Trajectories and Comorbidity Burden among Older 






Figure 2: The proportion of radiation treatment modalities used for prostate cancer has 
decreased while the use of surgery has increased over the years and the use of Brachytherapy 
has gone down while the use of external beam radiation therapy has remained relatively stable. 
(Burt, L. M., Shrieve, D. C., & Tward, J. D. (2018). Factors influencing prostate cancer patterns of 




Figure 3: The proportion of radiation treatment modalities used for prostate cancer has 
decreased while the use of surgery has increased from 1998 to 2010. (Martin, J. M., Handorf, E. 
A., Kutikov, A., Uzzo, R. G., Bekelman, J. E., Horwitz, E. M., & Smaldone, M. C. (2014). The 
rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized 







Graph 1: Overall trends in emergency room presentation for radiation gastroenteritis (ICD-9 
558.1) as a side effect of pelvic radiation therapy from Healthcare Cost and Utilization Project 
(AHRQ).  (Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality, 
Rockville, MD. https://hcupnet.ahrq.gov/.) 
 
 
Graph 2: Overall trends in rectal and anal hemorrhage (ICD-9 596.3) as a side effect of pelvic 
radiation therapy from Healthcare Cost and Utilization Project (AHRQ).  (Healthcare Cost and 
Utilization Project. Agency for Healthcare Research and Quality, Rockville, MD. 
https://hcupnet.ahrq.gov/.) 
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Graph 3: Recto-urethral fistula discharge rates in NIS have not changed during the time period 
analyzed. (Healthcare Cost and Utilization Project. Agency for Healthcare Research and 
Quality, Rockville, MD. https://hcupnet.ahrq.gov/) 
 
Graph 4: The HCUP NED database shows that emergency room visits for radiation cystitis 
(ICD-9 595.82, irradiation cystitis) increased over this time period. (Healthcare Cost and 
Utilization Project. Agency for Healthcare Research and Quality, Rockville, MD. 
https://hcupnet.ahrq.gov/.) 
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Graph 5: Logistic regression analysis shows the rates of discharges for both sexes per 100,000 
for radiation cystitis has increased significantly from 1997 to 2014. The rates for men increased 
significantly from 1997 to 2015. (Healthcare Cost and Utilization Project. Agency for Healthcare 
Research and Quality, Rockville, MD. https://hcupnet.ahrq.gov/) 
 
Graph 6: The median age for men discharged for radiation cystitis has increased from 74.6 
years in 1997 to 77.0 years in 2015.  (Healthcare Cost and Utilization Project. Agency for 
Healthcare Research and Quality, Rockville, MD. https://hcupnet.ahrq.gov/) 
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